ArticleChemical communications (Cambridge, England)2016
Discovery of a (19)F MRI sensitive salinomycin derivative with high cytotoxicity towards cancer cells.
Article in Chemical communications (Cambridge, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- First In Vitro Characterization of Salinomycinic Acid-Containing Two-Line Ferrihydrite Composites with Pronounced Antitumor Activity as MRI Contrast Agents.International journal of molecular sciences · 2025Article
- Urea and Thiourea Derivatives of Salinomycin as Agents Targeting Malignant Colon Cancer Cells.Anti-cancer agents in medicinal chemistry · 2025Article
- Therapeutic vulnerabilities of cancer stem cells and effects of natural products.Natural product reports · 2023Review
- Expeditive Synthesis of Potent C20-ACS organic & inorganic Au · 2022Article
- Rapid Access to Ironomycin Derivatives by Click Chemistry.ACS organic & inorganic Au · 2022Article
- Salinomycin as a potent anticancer stem cell agent: State of the art and future directions.Medicinal research reviews · 2022Review
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Article
- Click Chemistry in Natural Product Modification.Frontiers in chemistry · 2021Review
- Synthesis and Anticancer Activity of Dimeric Polyether Ionophores.Biomolecules · 2020Article
- Salinomycin kills cancer stem cells by sequestering iron in lysosomes.Nature chemistry · 2017Article
- Design, synthesis and evaluation of novelMedChemComm · 2016Article
Corrections and comments
- Erratum issued
Authors and funding
14 authors.
Funding
Abstract
Salinomycin is a promising anti-cancer agent which selectively targets cancer stem cells. To improve its potency and selectivity, an analog library of salinomycin was generated by site-specific modification and CuAAc derivatization. Through a cytotoxicity analysis of the library, a fluorinated analog with high potency, selectivity, and (19)F MRI sensitivity was discovered as a novel theranostic agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.